Nebenwirkungen · INOmax
INOmax 800 ppm mol/mol medicinal gas, compressed · Abschnitt 4.8 · PDF-Seite 20
HOS-108549 · Präparat HOS-093033
a: Identified from the clinical trial b: Identified from Post-Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures. Rapid rebound reactions such as intensified pulmonary vasoconstriction and hypoxia after sudden withdrawal of inhaled nitric oxide therapy has been described, precipitating cardiovascular collapse.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T11:01:00Z · SHA-256 4c3ecbe485d3d0d3f3d8a8b72af806e039310534c247a674f80a0286630fc6f8 · Passage b32c91ba5c19295272838ca680cf494ee215be40fce3f4c8eb61bfd957ca010c · Zeichen 3464–4127 im Abschnitt